TMCnet - World's Largest Communications and Technology Community



Chronic Hepatitis C Forecast in 12 Major Markets 2017-2027 - Research and Markets
[January 11, 2017]

Chronic Hepatitis C Forecast in 12 Major Markets 2017-2027 - Research and Markets

Research and Markets has announced the addition of the "Chronic Hepatitis C Forecast in 12 Major Markets 2017-2027" report to their offering.

Hepatitis C is a single-stranded RNA virus that infects and damages the liver. In most cases, hepatitis C causes no noticeable symptoms until the liver has been significantly damaged. Symptoms are often vague such as flu-like muscle aches and fatigue.

This report provides the current prevalent population for Chronic Hepatitis C across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, Russia, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Chronic Hepatitis C have been quantified and presented alongside the overall prevalnce figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Chronic hepatitis C is most often associated with co-infections with other chronic viral infections including:

- HIV Co-infection

- HBV Co-infection

- HCV co-infection

Likely downstream events associated with chronic HCV infection include:

- Cirrhosis of the liver

- Hepatocellular carcinoma

- Excess mortality associated with liver disease / decompensated liver function

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis (News - Alert) & Clinical Course

7. Key comorbid conditions/Features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line prevalence for Chronic Hepatitis C

10. Genotype of HCV infection in Chronic Hepatitis C patients

10.1 Predominant Genotype

11. Main route of infection for Chronic HCV patients

12. Major viral co-infection in Chronic HCV patients

13. Access to healthcare for CHCV patients

14. Events and outcomes for CHCV patients

15. Abbreviations used in the report

16. Patient-Based Offering

17. Online Pricing Data and Platforms

18. References

19. Appendix

For more information about this report visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy